Novel oral GRK2-biased β2 adrenergic receptor agonists show potential for safer glucose management and obesity treatment.
Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours , significantly faster versus placebo (p<0.0001)All ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback